Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

- Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose Selected -

- Phase 1 Expansion Cohorts for Patients with IDH1 Mutant Positive Glioma, Cholangiocarcinoma, Chondrosarcoma and Other Advanced Solid Tumors Are Open and Enrolling -

- Randomized Phase 2 Study of AG-120 in Cholangiocarcinoma Planned for 2016 -

- Company to Host Investor Event and Webcast Today -

CAMBRIDGE, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the fields of... More

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

- Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose Selected -

- Phase 1 Expansion Cohorts for Patients with IDH1 Mutant Positive Glioma, Cholangiocarcinoma, Chondrosarcoma and Other Advanced Solid Tumors Are Open and Enrolling -

- Randomized Phase 2 Study of AG-120 in Cholangiocarcinoma Planned for 2016 -

- Company to Host Investor Event and Webcast Today -

CAMBRIDGE, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the fields of... More

Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

- New Safety and Efficacy Data from Ongoing Studies of AG-221 and AG-120 to be Highlighted in Oral and Poster Presentations -

- Posters to Feature Pharmacokinetics and Pharmacodynamics Data for AG-348 and Findings from Natural History Study of Pyruvate Kinase Deficiency -

- Company to Host Investor Event and Webcast on December 7, 2015 -

CAMBRIDGE, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that new data from the ongoing dose-escalation and expansion studies of AG-221 and AG-120 in... More

Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

- New Safety and Efficacy Data from Ongoing Studies of AG-221 and AG-120 to be Highlighted in Oral and Poster Presentations -

- Posters to Feature Pharmacokinetics and Pharmacodynamics Data for AG-348 and Findings from Natural History Study of Pyruvate Kinase Deficiency -

- Company to Host Investor Event and Webcast on December 7, 2015 -

CAMBRIDGE, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that new data from the ongoing dose-escalation and expansion studies of AG-221 and AG-120 in... More

Agios Reports Third Quarter 2015 Financial Results

New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting

R&D Day Highlights Included Initiation of AG-221 Phase 3 "IDHENTIFY" Study, Design of AG-221 and AG-120 Frontline Combination Studies, and Selection of Second PKR Activator, AG-519, for Clinical Development

CAMBRIDGE, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the third quarter ended September 30,... More